Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Gemcitabine and Carboplatin for the Treatment of Locally Advanced or Metastatic, Progressive Urothelial Carcinoma

Trial Status: approved

This phase II trial tests how well giving gemcitabine and carboplatin works to treat patients with urothelial carcinoma that has spread to nearby tissue or lymph nodes (locally advanced) or that has spread from where it first started (primary site) to other places in the body (metastatic) and that is growing, spreading, or getting worse (progressive). Gemcitabine is a chemotherapy drug that blocks the cells from making DNA and may kill tumor cells. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of tumor cells. Giving gemcitabine and carboplatin may be effective in treating patients with locally advanced or metastatic, progressive urothelial carcinoma.